Breast Cancer Radiogenomics: Current Status and Future Directions
Publication date: January 2020Source: Academic Radiology, Volume 27, Issue 1Author(s): Lars J. Grimm, Maciej A. MazurowskiRadiogenomics is an area of research that aims to identify associations between imaging phenotypes (“radio-”) and tumor genome (“-genomics”). Breast cancer radiogenomics research in particular has been an especially prolific area of investigation in recent years as evidenced by the wide number and variety of publications and conferences presentations. To date, research has primarily been focused on dynamic contrast enhanced pre-operative breast MRI and breast cancer molecular subtypes, but investigations have extended to all breast imaging modalities as well as multiple additional genetic markers including those that are commercially available. Furthermore, both human and computer-extracted features as well as deep learning techniques have been explored. This review will summarize the specific imaging modalities used in radiogenomics analysis, describe the methods of extracting imaging features, and present the types of genomics, molecular, and related information used for analysis. Finally, the limitations and future directions of breast cancer radiogenomics research will be discussed.
This article summarizes the rationale for, and development of CDK inhibitors in melanoma, with their evolution from pan-CDK inhibitors to highly specific agents, throughout clinical trials and finally their potential future use. EXPERT OPINION: Whilst CDK inhibitors have been practice changing in breast cancer management, their efficacy is yet to be proven in melanoma. Combination with BRAF/MEK inhibitors has been hindered by dose-limiting toxicities, but their role may yet to be found within the spectrum of biomarker-derived personalized melanoma management. The effect that CDK inhibitors can have as an adjunct to imm...
Authors: Minami T, Kawano H, Sueyoshi E, Maemura K PMID: 33028777 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Mauro Vismara, Marta Zarà, Sharon Negri, Jessica Canino, Ilaria Canobbio, Silvia Stella Barbieri, Francesco Moccia, Mauro Torti, Gianni Francesco Guidetti
"She really, really reminded me a lot of my grandmother," Julia Arnaz says of her daughter, Desiree S. Anzalone
Publication date: Available online 8 October 2020Source: Journal of Biomedical InformaticsAuthor(s): Ziba Khandezamin, Marjan Naderan, Mohammad Javad Rashti
Kathy Siggins and Lynda Everman are thrilled to share the welcome news that the US Postal Service has reinstated sales of the Alzheimer’s Disease Research Semipostal Stamp effective October 5, 2020. It is now available for purchase at most post offices and online at https://store.usps.com/store/product/buy-stamps/alzheimers-S_564204, and by phone at 1-800 STAMP-24. Before it was withdrawn in November 2019, over 8.2 million stamps were sold during its two-year run raising $1,061,777 for NIH-supported research to advance better treatments, prevention, and one day, a cure of Alzheimer’s and related dementias. The ...
ConclusionWhile the presentation of CNS involvement was similar between the different age groups, younger patients had significantly longer CNS-free interval and longer overall survival, and for the subgroups of triple-negative patients, younger age at breast cancer diagnosis was associated with longer survival after diagnosis of CNS disease.
Authors: Yu L, Li P, Yang S, Guo P, Zhang X, Liu N, Wang J, Zhang W Abstract Aim: Breast cancer is a leading cause of cancer among women. Because guidelines on screening for breast cancer for certain ages are controversial, many experts advocate the use of shared decision making (SDM) using validated decision aids (DAs). Recent studies have concluded that DAs are beneficial; however, the results have great heterogeneity. Therefore, further studies are needed to improve understanding of these tools. Objective: This systematic review and meta-analysis aimed to investigate the impact of using web-based DAs in women ag...
Publication date: Available online 9 October 2020Source: International Journal of PharmaceuticsAuthor(s): Xiangshang Xu, Li Li, Xiaolan Li, Deding Tao, Peng Zhang, Jianping Gong
Conclusions Extended resection of the chest wall is associated in most cases with advanced disease, especially advanced breast cancer. Despite poor prognosis associated to locally advanced disease, it is imperative to perform chest wall reconstruction and allow the patient to continue adjuvant therapy (radiotherapy or chemotherapy) and improve quality of life.